Loading provider…
Loading provider…
Infectious Disease Physician in Durham, NC
NPI: 1396910543Primary Practice Location
DUKE UNIVERSITY HOSPITAL
2301 Erwin Rd, Durham, NC
Primary Employer
Duke Health Integrated Practice, Inc.
dhip.dukehealth.org
HQ Phone
Get MD Cameron's Phone Numberphone_androidMobile
Get MD Cameron's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 39 | 52 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 39 | 104 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 28 | 40 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 24 | 27 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 24 | 24 |
When you need to dive in the deep end-Transplanting SARS-CoV-2 PCR+ recipients.
Authors: Clare Delaurentis, Maria Segovia, Marcus Pereira, Benjamin Miko, Alyson Fox, Justin Aaron
Journal: Transpl Infect Dis
Publication Date: 2023-08-01
Authors: Richard Mularski, Mamta Jain, Susan Kline, Victor Tapson, Michelle Harkins, Robert Grossberg, Anne Luetkemeyer, Otto Yang, George Thompson Iii, Carlos Gomez, John Beigel, David Wyles, Allison Lambert, Maryrose Laguio-Vila, Philip Ponce, Daniel Sweeney, Nathaniel Erdmann, Catharine Paules, Thomas Patterson
Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept.
Authors: Eileen Maziarz, Brandon Menachem, Madeleine Heldman, Jennifer Saullo
Journal: Transpl Infect Dis
Publication Date: 2024-11-04
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: PPD Development, LP, Johns Hopkins University
Intervention / Treatment: BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine 2023-2024, BIOLOGICAL: Moderna COVID-19 Vaccine 2023-2024, DRUG: SOC IS Regimen, DRUG: SOC IS Reduction
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: OTHER: HIV D+/R+
Lead Sponsor: Duke University
Collaborators: Merck Sharp & Dohme LLC
Journal: Lancet Respir Med
Publication Date: 2021-10-18